Could a diabetes pill help fight HIV-related obesity?

NCT ID NCT07336797

Recruiting now Disease control Sponsor: Abdelrahman Mahmoud Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether empagliflozin, a diabetes drug, can help people with HIV who are overweight or obese lose weight and improve metabolic health. Researchers will enroll 66 adults with HIV who are on a specific antiretroviral therapy and have a BMI over 30. Participants will receive either empagliflozin or a placebo for 6 months to measure changes in weight, cholesterol, and blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV (HUMAN IMMUNODEFICIENCY VIRUS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome AIDS Body Weight HIV infectious disease metabolic syndrome X Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV (HUMAN IMMUNODEFICIENCY VIRUS) METABOLIC SYNDROME OBESITY & OVERWEIGHT

Contacts and locations

Locations

Faculty of Pharmacy, Cairo University | Kasr El-Aini, Cairo
RECRUITING

Cairo, 11562, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.